Carregant...
New and emerging concepts in the use of denosumab for the treatment of osteoporosis
Denosumab is a fully human monoclonal antibody to receptor activator of nuclear factor kappa-B ligand (RANKL), a cytokine expressed by cells of the osteoblast lineage that is a key regulator of osteoclastic bone resorption. By binding and neutralizing RANKL, denosumab inhibits osteoclast differentia...
Guardat en:
| Publicat a: | Ther Adv Musculoskelet Dis |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6204627/ https://ncbi.nlm.nih.gov/pubmed/30386439 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1759720X18805759 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|